Trial Profile
Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Fulvestrant
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 22 Aug 2018 Results of pooled analysis from 28 studies published in the Targeted Oncology
- 17 Apr 2018 Primary endpoint (Progression-free survival)has been met, as per the results published in the Journal of Clinical Oncology.
- 17 Apr 2018 Results assessing the effect of everolimus plus fulvestrant versus fulvestrant alone in postmenopausal women with ER-positive breast cancer published in the Journal of Clinical Oncology